Fig. 1

Median (a) and LS mean (b) change from baseline in anti-dsDNA (IU/mL). Data were assessed for significance in patients who were anti-dsDNA positive (≥30 IU/mL) at baseline. *p ≤0.05, **p≤0.01, ***p≤0.001 for BARI vs PBO. BARI, baricitinib; LS mean, least squares mean; PBO, placebo; dsDNA, double-stranded deoxyribonucleic acid